Guidewire Software Inc. Common Stock vs Mesoblast Limited — how do they compare? Guidewire Software Inc. Common Stock trades at $165.27 (market cap $13.59B), while Mesoblast Limited trades at $13.76 (market cap $1.83B). The key difference: Guidewire Software Inc. Common Stock is far larger — about 7.4× Mesoblast Limited's market cap, and Guidewire Software Inc. Common Stock is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Guidewire Software Inc. Common Stock for 0 Days and Mesoblast Limited for 15 Days on average.
| GWRE | MESO | |
|---|---|---|
Market Cap | $13.59B | $1.83B |
Volume | 838,274 | 259,445 |
Sector | Technology | Health |
52-Week High | $254.23 | $20.96 |
52-Week Low | $102.69 | $13.19 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $13.55B | $1.91B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MESO trades at $13.895, down 2.63% with bearish technical signals. The company reported substantial revenue growth to $120M in 2026 but remains unprofitable with a net margin of -47.82%. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant milestones. The stock shows mixed sentiment with 45% analyst buy ratings against bearish technical indicators.
While MESO demonstrates strong revenue growth potential and pipeline progress, persistent losses and negative profitability metrics present substantial risk. The company's cash position of $161M provides runway, but investors face volatility from clinical trial outcomes and path to profitability challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Guidewire Software Inc. develops InsuranceSuite Cloud, a software platform used by property and casualty insurers for policy administration, billing, and claims processing.
Read more on GWRE →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →